NFL Biosciences SA
ALNFL
Company Profile
Business description
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
Contact
199 rue Helene Boucher
Castelnau-le-Lez34170
FRAT: +33 411937667
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,966.70 | 3.20 | 0.04% |
| CAC 40 | 7,857.36 | 56.48 | 0.72% |
| DAX 40 | 24,217.37 | 247.01 | 1.03% |
| Dow JONES (US) | 44,625.45 | 212.11 | -0.47% |
| FTSE 100 | 9,136.32 | 54.88 | 0.60% |
| HKSE | 25,524.45 | 37.68 | -0.15% |
| NASDAQ | 21,134.43 | 44.16 | -0.21% |
| Nikkei 225 | 40,674.55 | 323.72 | -0.79% |
| NZX 50 Index | 12,936.41 | 25.67 | 0.20% |
| S&P 500 | 6,374.42 | 15.35 | -0.24% |
| S&P/ASX 200 | 8,704.60 | 6.90 | 0.08% |
| SSE Composite Index | 3,609.71 | 11.77 | 0.33% |